Key statistics
As of last trade Belite Bio Inc (D01:FRA) traded at 46.00, -0.86% below its 52-week high of 46.40, set on Jun 14, 2024.
52-week range
Open | 45.60 |
---|---|
High | 46.00 |
Low | 44.80 |
Bid | 46.20 |
Offer | 46.80 |
Previous close | 46.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.61m |
Free float | 29.50m |
P/E (TTM) | -- |
Market cap | 1.56bn USD |
EPS (TTM) | -1.23 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 18:55 BST.
More ▼
Announcements
- Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
- Belite Bio to Participate in Three Upcoming Investor Conferences
- Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
- Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
- Belite Bio to Present at the JonesHealthcare Seaside Summit
- Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
- Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
More ▼